Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)
Journal of Thrombosis and Haemostasis2014Vol. 13(3), pp. 360–369
Citations Over TimeTop 10% of 2014 papers
K. Kavakli, K. Kavakli, Renchi Yang, L. Rusen, H. Beckmann, D. Tseneklidou‐Stoeter, Monika Maas Enriquez, Renchi Yang, Yongqiang Zhao, Jing Sun, Xuefeng Wang, Depei Wu, Antonín Hluší, Katsuyuki Fukutake, Hideji Hanabusa, Teruhisa Fujii, Oscar Pérez Ramírez, Blanca Salazar Alvarado, M. Şerban, L. Rusen, Valentina Uscătescu, Cristina I. Truica, Gordana Kostić, Nada Konstantinidis, Zoran Igrutinović, F. G. Perina, T. A. Andreeva, Kaan Kavaklı, Kaan Kavaklı, Bülent Antmen, İlgen Şaşmaz, Alphan Küpesiz, M. Akif Yeşilipek, Ching‐Tien Peng, James French, Miguel A. Escobar, Johnny Mahlangu, Roger Pool
Abstract
Twice weekly or 3-times-weekly prophylaxis with BAY 81-8973 reduced median ABR by 97% compared with on-demand therapy, confirming the superiority of prophylaxis. Treatment with BAY 81-8973 was well tolerated.
Related Papers
- → Randomized Controlled Drug Trials on Very Elderly Subjects: Descriptive and Methodological Analysis of Trials Published Between 1990 and 2002 and Comparison With Trials on Adults(2005)36 cited
- → Randomized Controlled Trials for Creating Scientific Evidence of the Efficacy and Safety of Complementary and Alternative Medicine(2004)
- A compatision between one visit RCT and several visit RCT for cracked teeth.(2007)
- Ocular randomized and quasi-randomized contral trial in ophthalmologic journals(2003)
- Basical Clinical Observation of Cracked Tooth with One visit RCT(2003)